This AACR23 session will update the cancer research community on the FDA guidance and other various efforts from multiple stakeholders on the use of liquid biopsies in early-stage, solid tumor drug development. Jonathan Baden (Bristol Myers Squibb), co-chair of BLOODPAC's Analytical Validation working group, will be representing BLOODPAC on the panel.